Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved a revenue of 1.378 billion yuan in 2025, representing a year-on-year growth of 40.6%, and a net profit attributable to shareholders of 173.2 million yuan, reflecting a significant increase of 416% [7] - The company is positioned to benefit from the global competitive landscape in the model animal and preclinical CRO services, with a strong focus on antibody development integrated with AI technology [7] - The revenue from model animal sales reached 622 million yuan, up 59.9%, while preclinical CRO services generated 352 million yuan, up 75.2% [7] - The antibody development business generated 332 million yuan in revenue, marking a 42% increase, supported by the proprietary RenMice platform [7] - The company has established a robust AI model to enhance the efficiency of antibody development, which is expected to accelerate the release of potential candidates [7] - Revenue forecasts for 2026-2028 have been revised upwards, with expected revenues of 19.4 billion yuan and 25.5 billion yuan for 2026 and 2027, respectively [7] Financial Summary - Total revenue is projected to grow from 1.378 billion yuan in 2025 to 3.292 billion yuan by 2028, with a compound annual growth rate (CAGR) of approximately 29.15% [1][8] - The net profit attributable to shareholders is expected to increase from 173.2 million yuan in 2025 to 902.77 million yuan in 2028, indicating a strong growth trajectory [1][8] - The earnings per share (EPS) is forecasted to rise from 0.39 yuan in 2026 to 2.02 yuan in 2028, reflecting the company's improving profitability [1][8]
百奥赛图-B：2025年年报点评：模式动物和临床前CRO提速周期，抗体研发结合AI释放弹性-20260329